Lorem lacus proin sapien quis pretium quis praesent vel sit a blandit massa ornare molestie hendrerit non porttitor blandit dictum ornare laoreet non dolor massa congue adipiscing gravida sagittis libero amet congue vel volutpat ut eros orci venenatis nunc congue lacus accumsan nec accumsan sit proin quisque dictum dictum eleifend
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA clearance for the cobas® Factor II and Factor V Test for use on the cobas® 4800 system. The test enables laboratories to simultaneously assess Factor II and Factor V gene mutations from a single patient sample, which can reduce hands-on time when testing patients for inherited thrombophilia.
New test allows simultaneous processing of any combination of four separate sexually-transmitted infections (CT, NG, TV and MG) from one patient sample First and only high volume molecular test on market with approval for combination TV/MG testing using meatal …
New technology allows better testing and monitoring of HIV patients living in remote settings For the first time, patient plasma samples no longer need refrigeration during transport to the lab Card meets the World Health Organization sensitivity requirement for …
To download, please provide your contact information.
You are now leaving molecular.roche.com
The site you are about to visit is maintained by a third party. Roche Molecular Systems has no control over the content of third-party sites, nor does it endorse or accept attribution for the claims, comments and opinions expressed on them.
Click "Continue" to proceed or "Return" to return to molecular.roche.com.